Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivoi

被引:648
作者
Chen, ML
Pittet, MJ
Gorelik, L
Flavell, RA
Weissleder, R
von Boehmer, H
Khazaie, K
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA
[3] Harvard Univ, Sch Med, Charlestown, MA 02129 USA
[4] Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA
[5] Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA
关键词
D O I
10.1073/pnas.0408197102
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cancer patients can harbor significant numbers of CD8 and CD4 T cells with specificities to tumor antigens (Ags). Yet, in most cases, such T cells fail to eradicate the tumor in vivo. Here, we investigated the interference of Ag-specific CD4(+)CD25(+) regulatory T cells (Treg) with the tumor-specific CD8 T cell immune response in vivo, by monitoring the homing, expansion, and effector function of both subsets in draining and nondraining lymph nodes. The results show that CD8 cells expand to the same extent and produce similar levels of IFN-gamma in the presence or absence of Ag-specific Treg. Nevertheless, these Treg abrogate CD8 T cell-mediated tumor rejection by specifically suppressing the cytotoxicity of expanded CD8 cells. The molecular mechanism of suppression involves TGF-beta because expression of a dominant-negative TGF-beta receptor by tumor-specific CD8 cells renders them resistant to suppression and is associated with tumor rejection and unimpaired cytotoxicity.
引用
收藏
页码:419 / 424
页数:6
相关论文
共 41 条
[1]   Origin of regulatory T cells with known specificity for antigen [J].
Apostolou, I ;
Sarukhan, A ;
Klein, L ;
von Boehmer, H .
NATURE IMMUNOLOGY, 2002, 3 (08) :756-763
[2]   The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis [J].
Blankenstein, T ;
Qin, ZH .
CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (02) :148-154
[3]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[4]   CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism [J].
Dai, ZH ;
Li, Q ;
Wang, YN ;
Gao, G ;
Diggs, LS ;
Tellides, G ;
Lakkis, FG .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (02) :310-317
[5]   Functional impairment of CD8+ T cells by regulatory T cells during persistent retroviral infection [J].
Dittmer, U ;
He, H ;
Messer, RJ ;
Schimmer, S ;
Olbrich, ARM ;
Ohlen, C ;
Greenberg, PD ;
Stromnes, IM ;
Iwashiro, M ;
Sakaguchi, S ;
Evans, LH ;
Peterson, KE ;
Yang, GJ ;
Hasenkrug, KJ .
IMMUNITY, 2004, 20 (03) :293-303
[6]  
Erard F, 1999, J IMMUNOL, V162, P209
[7]   Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state [J].
Fisson, S ;
Darrasse-Jèze, G ;
Litvinova, E ;
Septier, F ;
Klatzmann, D ;
Liblau, R ;
Salomon, BL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (05) :737-746
[8]   Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease [J].
Gorelik, L ;
Flavell, RA .
IMMUNITY, 2000, 12 (02) :171-181
[9]   Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells [J].
Gorelik, L ;
Flavell, RA .
NATURE MEDICINE, 2001, 7 (10) :1118-1122
[10]   CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-β-TGF-β receptor interactions in type 1 diabetes [J].
Green, EA ;
Gorelik, L ;
McGregor, CM ;
Tran, EH ;
Flavell, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (19) :10878-10883